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Tuberculosis (TB) is a major health problem requiring an appropriate cell immune response (IR) to be controlled. Since regulatory
T cells (Tregs) are relevant in IR regulation, we analyzed Tregs variations throughout the course of TB treatment and its relationship
with changes in immune-endocrine mediators dealing with disease immunopathology. The cohort was composed of 41 adult
patients, 20 of them completing treatment and follow-up. Patients were bled at diagnosis (T0) and at 2 (T2), 4 (T4), 6 (T6), and 9
months following treatment initiation. Twenty-four age- and sex-matched healthy controls (HCo) were also included. Tregs (flow
cytometry) from TB patients were increased at T0 (versus HCo 𝑃 < 0.05), showing even higher values at T2 (versus T0 𝑃 < 0.01)
and T4 (versus T0 𝑃 < 0.001). While IL-6, IFN-𝛾, TGF-𝛽 (ELISA), and Cortisol (electrochemiluminescence, EQ) were augmented,
DHEA-S (EQ) levels were diminished at T0 with respect to HCo, with cytokines and Cortisol returning to normal values at T9.
Tregs correlated positively with IFN-𝛾 (𝑅 = 0.868, 𝑃 < 0.05) at T2 and negatively at T4 (𝑅 = −0.795, 𝑃 < 0.05). Lowered levels of
proinflammatory cytokines together with an increased frequency of Tregs of patients undergoing specific treatment might reflect
a downmodulatory effect of these cells on the accompanying inflammation.
1. Introduction
According the World Health Organization one third of the
world population is infected withMycobacterium tuberculosis
(Mtb), and the majority of affected people are found in
developing countries. The situation becomes even more
problematical because of the increased susceptibility of HIV
infected persons to develop the disease and the emergence of
strains resistant to the antimicrobial therapy [1].
Most people infected with Mtb have a clinically latent
infection and 10% of them further progress to active TB dur-
ing their lifetime. Bacterial, host, and environmental factors
influence the development of active TB [1, 2]. Commonly,
the host immune response (IR) controls Mtb replication,
collaborating with the establishment of latent infection,
which ultimately depends on a fine balance between the
pathogen persistence and the specific IR [3]. T cell-mediated
immunity is the main response against TB, mainly through
interferon-gamma (IFN-𝛾) production by antigen specific T
cells. However an exacerbated effector IR and the ensuing
excessive secretion of inflammatory mediators turn out to be
detrimental damaging host tissues through immunopatho-
logical processes. It follows that a properly balanced IR is
essential to successfully cope with this pathogen [4].
Regulatory T cells which tend to modulate the anti-
infectious host immunity are currently viewed as one of the
suitable mechanisms for Th-1-dependent immune response
suppression. Among these T cell subpopulations, those
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expressing intracellular transcription factor FoxP3 seem to
display the most functional activity in terms of immuno-
suppression. FoxP3-positive regulatory T cells (Tregs) can be
either natural, in the course of antigen-dependent thymic
differentiation, or induced in the periphery during adaptive
immune responses [5]. Tregs represent 5–10% of circulating
CD4+ cells but in humans only the subset expressing higher
levels of CD25 (𝛼 chain of IL-2R) exhibits a strong suppressive
capacity [6]. The main mechanisms of suppression by Treg
cells include inhibition of IFN-𝛾 production by T cells
through the production of IL-10 and transforming growth
factor beta (TGF-𝛽), as well as by cell to cell contact [7].While
evidence indicates that Tregs are involved in the immune
response against Mtb, there is no consensus regarding the
precise role of Treg in TB.
Some studies reported Treg cell expansion in the blood,
lung, or other tissues of patients with active TB [8, 9],
suggesting that these cells may suppress T cell immunity and
hence contribute to disease development [6, 10]. In contrast,
other studies reported no increase of Treg in TB patients [11,
12]. A recent work carried out in nonhuman primates raised
the view of increased Treg as representing a counterbalancing
anti-inflammatory response instead of an immunosuppressor
effect [7]. Collectively, it may be assumed that Tregs are
likely to have a differential role on infection outcomes
depending on the proper balance between protective immune
mechanisms and those involved with tissue damage.
In parallel, other extrinsic mechanisms may also con-
tribute to reduce inflammation during immunologically
based diseases, partly because of the neuroimmunoendocrine
communication, in particular the hypothalamus-pituitary-
adrenal (HPA) axis, that attempts to maintain immune
homeostasis. As key molecules of the HPA axis, endoge-
nous adrenal steroids (Cortisol, Dehydroepiandrosterone
(DHEA)) contribute to modulate the immune response to
infectious agents and other insults. In turn, the HPA axis
is modulated by cytokines like IFN-𝛾 and IL-6, which are
produced during the immune response. Within this setting,
we have observed that patients with pulmonary TB have
imbalanced immune-endocrine responses with increased
plasma concentrations of proinflammatory cytokines and
Cortisol, in presence of decreased DHEA levels associated
with disease severity [13, 14].
In expanding the knowledge about the participation of
Treg in TB, the analysis of this T cell population throughout
the course of TB treatment and its eventual relationship with
changes in immune-endocrine mediators involved in disease
immunopathology is informative. According to this we have
proceeded to characterize this T cell population at different
time points following treatment initiation along with the
assessment of cytokines and hormones critically to contain
an infectious threat.
2. Materials and Methods
2.1. Subjects. Between January 2010 and January 2014, adults
who were diagnosed with lung TB based on clinical and
radiological findings and identification of TB bacilli in
sputum were enrolled and followed for up to nine months in
a prospective cohort study of Mtb infection and treatment.
This observational cohort included forty-one patients, with
neither HIV coinfection nor multidrug resistant TB. Patients
had mild (𝑛 = 7), moderate (𝑛 = 16), or advanced
(𝑛 = 18) disease according to the radiological findings, as
previously described [13]. Antituberculosis therapy consisted
of six months of rifampicin and isoniazid, initially supple-
mented by two months of pyrazinamide and ethambutol.
Of the 41 recruited patients, blood samples at all time
points were available in 20 of them (mild = 1, moderate =
12, and severe = 7). Twenty-four matched healthy subjects
(HCo), living in the same area and without antecedents of
contactwithTBpatients, were included as controls. Exclusion
criteria for all participants included pathologies affecting the
hypothalamus-pituitary-thyroid- or gonadal-axis, or direct
compromise of the adrenal gland, pregnancy, contraceptive
drugs, age under 18, or systemic or localized pathologies
requiring treatment with corticosteroids or immunosuppres-
sants. All subjects were BCG vaccinated and providedwritten
consent to participate in the study.The studywas approved by
the Ethical Committee of the Facultad de Ciencias Me´dicas,
Universidad Nacional de Rosario and Centenario Hospital of
Rosario.
2.2. Sample Collection. Blood samples were obtained from
TB patients at the time of diagnosis (before initiation of the
treatment, T0) and 2, 4, and 6 months (T2, T4, and T6) after
starting the specific antituberculosis treatment. An additional
sample was obtained three months after the end of treatment
completion (T9). All samples were obtained between 8:00
and 9:00 a.m. with and without EDTA and then centrifuged.
Aprotinin (100U/mL; Aprotinin from bovine lung, Sigma-
Aldrich, St. Louis,MO,USA)was added to the plasma shortly
after collection and the samples were preserved at −20∘C.
Serum samples were immediately processed for hormone
quantification.One blood samplewas obtained from age- and
sex-matched HCo and processed in the same way.
2.3. Sample Preparation. Twenty milliliters of blood was
obtained using EDTA as anticoagulant, and the PBMC were
obtained by Ficoll-Hypaque density gradient centrifugation
(Biowittaker, Walkersville, MD). PBMC were washed twice
in PBS and counted by trypan blue staining in a Neubauer
chamber. Viability was always of 95%.
2.4. Flow Cytometry. For surface marker analyses, a sample
of 50 𝜇L of well-mixed EDTA anticoagulated whole blood
was incubated for 30min at room temperature with 20𝜇L
of BD Tritest CD4 FITC/CD8 PE/CD3 PerCP Reagent (BD
Biosciences, San Jose, CA, USA) according to manufacturer
instructions. Following incubation, red blood cells were lysed
withNaHCO
3
/ClNH
4
solution. Cells were washed twice with
PBS and preserved for cytometric analysis.
Another sample of 1 × 106 PBMC was incubated for
30min with anti-CD4-FITC and anti-CD25-PEcy5.5 (BD
Biosciences, San Jose, CA, USA) and for intracellular staining
of FoxP3, the cells in the tubes were resuspended in Fix/Perm
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buffer (eBioscience, San Diego, CA, USA) and left at 4∘C
for 30min. Subsequently, these cells were washed with cold
PBS and with permeabilization buffer (eBioscience, San
Diego, CA, USA) and then 20 𝜇L anti-human FoxP3-PE (BD
Biosciences, San Jose, CA,USA) was added and the cells were
incubated at 4∘C for 30min. Stained cells were analyzed with
a FACSAria II flow cytometer (BD Biosciences, San Jose,
CA, USA). The percentage of positive cells and the mean
fluorescence intensity (arbitrary units) for a specific marker
were calculated using FACSDiva software (BD Biosciences,
San Jose, CA, USA). For purpose analysis 30000 events were
recorded.
2.5. Evaluation of Immunological Mediators and Hormones.
Levels of TGF-𝛽, IFN-𝛾, and IL-6 were measured in plasma
using commercially available high-sensitivity ELISA kits
according to the instructions of the manufacturer. Detec-
tion limits were 0.07 pg/mL for IL-6 (R&D Systems, Inc.
Minneapolis, USA), 125 pg/mL for TGF-𝛽, and 4.7 pg/mL
for IFN-𝛾 (both from BD Bioscience, San Jose, CA, USA).
Cortisol and DHEA-sulphated (DHEA-S) serum concen-
trations were assessed by electrochemiluminescence (Cobas
e411, Roche, Germany).
2.6. Statistical Analysis. Comparisons between groups (TB
versus HCo) were performed by nonparametric methods,
(Kruskall-Wallis analysis of variance and Mann-Whitney 𝑈
test). Correlations between variables were assessed by Spear-
man’s rank test. Data were considered statistically significant
when𝑃 < 0.05.The analyseswere performedusingGraphPad
Prism 4 Software.
3. Results
3.1. CD4+CD25+FoxP3+ T Cells Are Increased in the Blood of
Patients with TB. Table 1 shows some general characteristics
of study groups. All patients showed a decreased Body
Mass Index (BMI) (𝑃 < 0.001). There were no differences
with respect to age, sex distribution, BCG-vaccination, and
peripheral CD8+ T cells frequency. However, we found that
TB patients presented a significant diminution inCD4+T cell
levels (𝑃 < 0.05).Thenwe investigatedwhether active TBwas
associated with a CD4+CD25+FoxP3+ Treg expansion by
assessing their frequency in PBMC of TB patients at the time
of diagnosis by flow cytometry (Figure 1(a)). Results depicted
in Figure 1(b) indicate that the frequency of Treg cells within
the total CD4+ population was significantly increased in TB
patients compared with HCo (𝑃 < 0.05). We next analyzed
the percentage of Treg cells in TB patients according to their
severity. As seen in Figure 1(c), moderate TB patients differed
from HCo.
3.2. Treg Frequency during Antituberculosis Therapy. In ear-
lier studies, we have evaluated immune and endocrine
parameters during TB treatment, showing that certain
cytokines were augmented at the time of diagnosis (IL-
1𝛽, IL-6, and IFN-𝛾) and even 2 months after treatment
initiation (IFN-𝛾) [15]. In relation to peripheral T cells, we
Table 1: Characteristics of study groups.
HCo (𝑛 = 24) TB (𝑛 = 41) 𝑃 value
Age (years)∗ 50.5 (25.8–57.3) 45.0 (21.5–54.8) ns
Sex (F/M) 1/23 4/37 ns
BCG (%) 95% 80% ns
BMI (Kg/m2)∗ 27.4 (25.1–30.8) 19.9 (18.3–23.8) 𝑃 < 0.001
%CD4+∗ 51.4 (43.0–55.1) 39.4 (32.6–52.6) 𝑃 < 0.05
%CD8+∗ 33.0 (24.6–35.8) 25.2 (21.8–33.4) ns
∗Results are shown as median values (25–75 percentiles). HCo: healthy
controls.
found a decrease in the percentages of CD3+ CD4+ cells
at the time of diagnosis that attained normal values upon
starting specific treatment (data not shown). When assessing
the frequency of Tregs throughout specific treatment, these
cell populations remained significantly increased during that
period compared to values in HCo, reaching their highest
relative levels at T4 (HCo versus T4 𝑃 < 0.01, Figure 2).
3.3. Correlations between Treg Frequency and Cytokine and
Hormone Levels. TGF-𝛽, IFN-𝛾, and IL-6 plasma levels
were assessed at the beginning and at different time points
during anti-TB treatment. Table 2 shows median values and
interquartile range for each cytokine at the study time points.
The three cytokines were increased at the time of diagnosis
with respect HCo, returning to normal values once patients
initiated specific treatment. Pairwise correlations between
cytokines and Treg frequency revealed that IFN-𝛾 levels
were positively associated with % Treg at month two under
treatment (𝑅 = 0.868, 𝑃 < 0.05, 𝑛 = 8). Notably, this
correlation became negative when patients underwent four
months of specific treatment (𝑅 = −0.798, 𝑃 < 0.05,
𝑛 = 9; see Supplementary Material available online at
http://dx.doi.org/10.1155/2015/985302). In a further step TB
patients were categorized according to their IFN-𝛾 levels at
T4. In this way patients with values below the median value
had significantly higher levels of Treg cells when compared
with cases whose plasma IFN-𝛾 is situated above the median
concentration (𝑃 = 0.027).
With regard to adrenal hormones, serum Cortisol was
increased at the time of diagnosis (𝑃 < 0.01) and at T2
(𝑃 < 0.01), reaching values comparable toHCo at T4.DHEA-
S levels which were found decreased at T0 (versus HCo 𝑃 <
0.05) remained so during the whole treatment period but
were augmented at T9 reaching values similar to those seen in
HCo. Unlike this DHEA-S levels which were found strongly
decreased at diagnosis started to increase earlier following
treatment initiation (data not shown). Both adrenal steroids
showed a negative correlation with the frequency of Treg
cells, DHEA-S at the time of diagnosis (𝑅 = −0.51, 𝑃 < 0.04,
𝑛 = 13), and Cortisol at T4 (𝑅 = −0.504, 𝑃 < 0.05, 𝑛 = 12; see
Supplementary Material).
4. Discussion
The involvement of Treg cells in the control of immune
responses to self-antigens and in immune homeostasis is well
4 Journal of Immunology Research
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Figure 1: CD4+CD25+FoxP3+ T cells (Tregs) frequency in TB patients. (a) Plot of cytometric analysis from a representative sample: (I) FSC
and SSC identifying mononuclear cells, (II) CD4+ cells within the lymphocyte gate, (III) assessment of FoxP3+ cells gated on the CD4+ cells
as shown in panel II, (IV) isotype control from the same sample, and (V) an additional control showing that the CD4+FoxP3+ population is
also CD25 high. (b) Treg % comparisons between HCo and TB. (c) Comparisons of disease severity of TB patients. Box plots show median
values, 25–75 percentiles of data in each group with maximum and minimum values. HCo: healthy controls.
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Figure 2: Frequency of CD4+CD25+FoxP3+ T cells (Tregs) within
the total CD4+population of TBpatients throughout treatment. Box
plots show median values, 25–75 percentiles of data in each group
with maximum and minimum values. HCo: healthy controls. T0:
time of diagnosis; T2, T4, T6: 2, 4, and 6 months after starting the
specific anti-TB treatment; T9: 3 months after the end treatment
completion. ∗HCo versus T0 and T6 𝑃 < 0.05; HCo versus T2 and
T4 𝑃 < 0.01. #T0 versus T2 𝑃 < 0.05; T0 versus T4 𝑃 < 0.01; 󸀠󸀠T4
versus T9 𝑃 < 0.05.
established. Also there is increasing evidence for a role of Treg
in the regulation of immunity to infection [16]. It is believed
that Treg downmodulate the IR after pathogen eradication
to avoid exacerbated pathology. Although this mechanism
benefits the host during acute infections, it may be worrying
in the chronic setting, notably when pathogen persistence
is sustained in spite of an active IR [10]. During chronic
infections, a complex interplay is established between the IR
to the infectious agent and the ability of the microorganism
to evade this protective IR. In TB, a predominantTh1 cellular
response is necessary to effectively eradicate the mycobac-
terium. However if this response exacerbates, certain regu-
latory mechanisms would be activated to downmodulate it
with the aimof safeguarding the affected organ, at the expense
of some interference with pathogen clearance. One of these
regulatory mechanisms involves Treg [5]. CD4+CD25 high T
cells have been reported to be present at elevated levels in TB
and to be able to depress T-cell-mediated IFN-𝛾 production
in these patients [4, 8, 9, 17]. Here, we show that TB patients
have an increased frequency of CD4+CD25+FoxP3 Treg in
comparison with the group of healthy donors. Furthermore,
the frequency remained augmented at two and four months
of treatment commencement, reaching values comparable to
those seen HCo once the treatment was completed. Tregs
are known to display a diverse range of Treg-mediated
immunological effects, in terms of antimicrobial and tissue-
damage protection. In this case, the increased presence of
Treg cells seems to be more compatible with an attempt
to downmodulate immunological damage, considering our
former [14, 18] and present demonstrationswherein advanced
TB coexisted with increased levels of circulating proinflam-
matory cytokines.
The role of Tregs in TB is not well understood; and it
is unclear whether their expansion is a cause or a disease
consequence. As stated, they are probably expanded as an
adaptive host response to limit the inflammatory reaction and
tissue damage induced. Tregs expansion duringMtb infection
upon recognition of particular bacterial antigens seems to
be achieved by the presence of IL-10 and TGF-𝛽, which are
known to be highly produced in patients with active TB
[14, 17, 19, 20]. Some studies reported a higher suppressive
capacity of Tregs on IFN-𝛾 producing cells with respect to
those producing IL-17, which allowed the persistence of the
latter ones in inflamed tissues and thus the perpetuation
or recrudescence of inflammation [6, 21, 22]. Our results
about a significant positive correlation between Tregs and
IFN-𝛾 plasma levels at two months of treatment suggest that
increased Tregs are not downmodulating inflammation, at
this stage. However at T4 when the clinical improvement was
quite evident, this correlation turned out to be negative. It
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follows that month 4 might represent the best time when
a proper balance between Treg functioning and clinical
response is established.
The negative correlations between adrenal steroids and
the frequency of Treg cells are also worth discussing. Glu-
cocorticoids are potent anti-inflammatory and immunosup-
pressive agents, playing a role in the feedback inhibition of
immune/inflammatory responses to maintain homeostasis.
Xiang andMarshall Jr. demonstrated that after 24 h of culture
of PBMC with dexamethasone (10−8M) FoxP3 mRNA was
significantly decreased, suggesting a rapid sensitivity of Treg
to corticosteroids [23]. In the same sense, DHEA was also
found to inhibit FoxP3 expression in HIV-coinfected TB
patients [24]. In line with these in vitro findings, in our
patients the frequency of Treg cells was inversely correlated
with the amount of adrenal steroids implicating an extra loop
of influence on this T cell population which is beyond the
intrinsic immunological components.
Ribeiro-Rodrigues et al. showed that frequencies of Treg
were increased in PBMC of patients with active tuberculosis
and did not decline at the end of 6 months of curative
antibiotic therapy. At this time point, Treg still preserved
their capacity to suppress IFN-𝛾 production [25]. Chen et
al. evaluated Treg frequencies in pulmonary tuberculosis
patients after 2 years of chemotherapy and found a direct
correlation between the decreased levels of Treg toward
normality in patients successfully recovered, as seen in our
case. This group also found that Tregs from tuberculosis
patients not only suppress IFN-𝛾 production but also inhibit
IL-10 production by CD4+ T cells [26].
To conclude, the persistent increase of Tregs until 4
months of specific treatment in presence of diminished
amounts of proinflammatory cytokines alongwith the inverse
association between both immune parameters, lend some
support to the view of a damage-protective function of Tregs
in TB. Further functional studies are now being planned to
assess the validity of the assumption of Tregs as counterbal-
ancing the excessive inflammatory response encompassing
this disease.
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